Delta Asset Management LLC TN Sells 1,128 Shares of Johnson & Johnson (NYSE:JNJ)

Delta Asset Management LLC TN decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 43,174 shares of the company’s stock after selling 1,128 shares during the quarter. Delta Asset Management LLC TN’s holdings in Johnson & Johnson were worth $6,244,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. IFS Advisors LLC grew its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $35,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in Johnson & Johnson in the fourth quarter worth approximately $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $161.64 on Thursday. The company has a 50-day simple moving average of $158.04 and a two-hundred day simple moving average of $156.18. The company has a market capitalization of $389.54 billion, a PE ratio of 24.31, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the firm earned $2.29 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.07%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insiders Place Their Bets

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on JNJ shares. Citigroup decreased their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Stifel Nicolaus cut their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.